Cardiovascular Effects of Losartan and Its Relevant Clinical Application

Overview

Journal Curr Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2009 Sep 15

PMID 19747137

Citations 14

Authors

Feichao Xu

Caiping Mao

Yali Hu

Can Rui

Zhice Xu

Lubo Zhang

Affiliations

Soon will be listed here.

Abstract

The renin-angiotensin system (RAS) plays an important role in the homeostasis of the cardiovascular system and in the development of cardiovascular diseases. An abnormal expression or over activation of the local RAS in the heart and vasculature system is one of the most common mechanisms in pathophysiological processes in cardiovascular diseases. This also provides a basis for medical prevention and treatments using chemical approaches. Losartan is a selective nonpeptite antagonist against type 1 angiotensin II receptors (AT1R), and has been applied in medical treatments of a variety of cardiovascular diseases, including essential hypertension. This article reviews direct and indirect cardiovascular effects of losartan on the heart and blood vessels. It summarizes the chemical basis of AT1R for the action site of losartan,focuses on the mechanisms underlying the action of losartan involved in both the heart and vasculature, and reviews the information that may be helpful in the development of new chemical candidates or approaches in the war against cardiovascular diseases.

Citing Articles

Capillary pruning couples tissue perfusion and oxygenation with cardiomyocyte maturation in the postnatal mouse heart.

Santamaria R, Cruz-Caballero J, Gkontra P, Jimenez-Montiel A, Clemente C, Lopez J Front Cell Dev Biol. 2023; 11:1256127.

PMID: 38020883 PMC: 10661946. DOI: 10.3389/fcell.2023.1256127.

The Impact of Some Modulators of the Renin-Angiotensin System on the Scopolamine-Induced Memory Loss Mice Model.

Ababei D, Balmus I, Bild W, Ciobica A, Lefter R, Rusu R Brain Sci. 2023; 13(8).

PMID: 37626567 PMC: 10452197. DOI: 10.3390/brainsci13081211.

Renin-Angiotensin System Antagonism Protects the Diabetic Heart from Ischemia/Reperfusion Injury in Variable Hyperglycemia Duration Settings by a Glucose Transporter Type 4-Mediated Pathway.

Al-Kouh A, Babiker F, Al-Bader M Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259385 PMC: 9967344. DOI: 10.3390/ph16020238.

Effects of a Losartan-Antioxidant Hybrid (GGN1231) on Vascular and Cardiac Health in an Experimental Model of Chronic Renal Failure.

Martinez-Arias L, Fernandez-Villabrille S, Alonso-Montes C, Garcia-Navazo G, Ruiz-Torres M, Alajarin R Nutrients. 2023; 15(8).

PMID: 37111038 PMC: 10143556. DOI: 10.3390/nu15081820.

Effects of Long-Term Intervention with Losartan, Aspirin and Atorvastatin on Vascular Remodeling in Juvenile Spontaneously Hypertensive Rats.

Liu Q, Dong S, Zhou X, Zhao Y, Dong B, Shen J Molecules. 2023; 28(4).

PMID: 36838830 PMC: 9965824. DOI: 10.3390/molecules28041844.

References

Beilin L, Goldby F, Mohring J . High arterial pressure versus humoral factors in the pathogenesis of the vascular lesions of malignant hypertension. Clin Sci Mol Med. 1977; 52(2):111-7. DOI: 10.1042/cs0520111. View

Burrell L, Risvanis J, Kubota E, Dean R, Macdonald P, Lu S . Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005; 26(4):369-75. DOI: 10.1093/eurheartj/ehi114. View

Landmesser U, Hornig B, Drexler H . Endothelial function: a critical determinant in atherosclerosis?. Circulation. 2004; 109(21 Suppl 1):II27-33. DOI: 10.1161/01.CIR.0000129501.88485.1f. View

Gimbrone Jr M, Alexander R . Angiotensin II stimulation of prostaglandin production in cultured human vascular endothelium. Science. 1975; 189(4198):219-20. DOI: 10.1126/science.1138377. View

Andersen S, Rossing P, Juhl T, Deinum J, Parving H . Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant. 2002; 17(8):1413-8. DOI: 10.1093/ndt/17.8.1413. View

Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer J . Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002; 109(11):1417-27. PMC: 150992. DOI: 10.1172/JCI14276. View

Goette A, Lendeckel U, Klein H . Signal transduction systems and atrial fibrillation. Cardiovasc Res. 2002; 54(2):247-58. DOI: 10.1016/s0008-6363(01)00521-1. View

Ichihara S, Senbonmatsu T, Price Jr E, Ichiki T, Gaffney F, Inagami T . Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation. 2001; 104(3):346-51. DOI: 10.1161/01.cir.104.3.346. View

Senbonmatsu T, Ichihara S, Price Jr E, Gaffney F, Inagami T . Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest. 2000; 106(3):R25-9. PMC: 314331. DOI: 10.1172/JCI10037. View

10.

Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R . Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005; 115(8):2108-18. PMC: 1180541. DOI: 10.1172/JCI24682. View

11.

Crabos M, Roth M, Hahn A, Erne P . Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest. 1994; 93(6):2372-8. PMC: 294443. DOI: 10.1172/JCI117243. View

12.

Laverman G, Henning R, de Jong P, Navis G, de Zeeuw D . Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis. 2001; 38(6):1381-4. DOI: 10.1053/ajkd.2001.29262. View

13.

Sutton M, Sharpe N . Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000; 101(25):2981-8. DOI: 10.1161/01.cir.101.25.2981. View

14.

Nattel S, Opie L . Controversies in atrial fibrillation. Lancet. 2006; 367(9506):262-72. DOI: 10.1016/S0140-6736(06)68037-9. View

15.

Sano M, Fukuda K, Kodama H, Pan J, Saito M, Matsuzaki J . Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem. 2000; 275(38):29717-23. DOI: 10.1074/jbc.M003128200. View

16.

Dostal D, Baker K . The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function?. Circ Res. 1999; 85(7):643-50. DOI: 10.1161/01.res.85.7.643. View

17.

Liggett S, Tepe N, Lorenz J, Canning A, Jantz T, Mitarai S . Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. 2000; 101(14):1707-14. DOI: 10.1161/01.cir.101.14.1707. View

18.

Pinto Y, Buikema H, van Gilst W, Scholtens E, Geel P, de Graeff P . Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats. J Mol Med (Berl). 1997; 75(5):371-7. DOI: 10.1007/s001090050123. View

19.

Crawford D, CHOBANIAN A, Brecher P . Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res. 1994; 74(4):727-39. DOI: 10.1161/01.res.74.4.727. View

20.

Weir R, Balmain S, Steedman T, Ng L, Squire I, Rumley A . Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction. J Thromb Thrombolysis. 2009; 29(4):421-8. DOI: 10.1007/s11239-009-0383-6. View